Phospholipid Abnormalities in Children with Barth Syndrome

Michael Schlame, Richard I. Kelley, Annette Feigenbaum, Jeffrey Towbin, Paul M. Heerdt, Thomas Schieble, Ronald J.A. Wanders, Salvatore DiMauro, Thomas J.J. Blanck

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

OBJECTIVES: We sought to identify characteristic lipid abnormalities in patients with Barth syndrome (BTHS) and to correlate the lipid profile to phenotype and genotype. BACKGROUND: Barth syndrome typically includes cardiomyopathy, skeletal myopathy, neutropenia, growth retardation, and 3-methylglutaconic aciduria, and it is commonly associated with mutations in the tafazzin (TAZ) gene, whose products are homologous to phospholipid acyltransferases. However, clinical features of BTHS have also been found in patients with normal TAZ gene. METHODS: We analyzed molecular species of phospholipids in left and right ventricle, skeletal muscle, platelets, lymphoblasts, and fibroblasts from 19 children with BTHS (positive TAZ mutation), 6 children with BTHS-like syndromes (wild-type TAZ), 4 children with isolated cardiomyopathy (wild-type TAZ), and various controls. RESULTS: Cardiolipin, the specific lipid found only in mitochondria, was decreased in all tissues from BTHS patients, whereas concentrations of other phospholipids were normal. The molecular composition of cardiolipin was altered in all tissues from BTHS patients. The molecular compositions of phosphatidylcholine and phosphatidylethanolamine were altered in the heart. Cardiolipin abnormalities were only found in children with true BTHS, not in children with BTHS-like disease or with isolated cardiomyopathy. The degree of cardiolipin deficiency was tissue-specific but did not correlate with severity or specific phenotypic expression of BTHS. CONCLUSIONS: Abnormal cardiolipin is a specific diagnostic marker of cardiomyopathies caused by TAZ mutations. These mutations lead to alterations in the fatty acid composition of several phospholipids, supporting the idea that TAZ encodes a human acyltransferase.

Original languageEnglish (US)
Pages (from-to)1994-1999
Number of pages6
JournalJournal of the American College of Cardiology
Volume42
Issue number11
DOIs
StatePublished - Dec 3 2003
Externally publishedYes

Fingerprint

Barth Syndrome
Phospholipids
Cardiolipins
Cardiomyopathies
Mutation
Lipids
Heart Ventricles
Acyltransferases
Muscular Diseases
Neutropenia
Phosphatidylcholines
Genes

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Schlame, M., Kelley, R. I., Feigenbaum, A., Towbin, J., Heerdt, P. M., Schieble, T., ... Blanck, T. J. J. (2003). Phospholipid Abnormalities in Children with Barth Syndrome. Journal of the American College of Cardiology, 42(11), 1994-1999. https://doi.org/10.1016/j.jacc.2003.06.015

Phospholipid Abnormalities in Children with Barth Syndrome. / Schlame, Michael; Kelley, Richard I.; Feigenbaum, Annette; Towbin, Jeffrey; Heerdt, Paul M.; Schieble, Thomas; Wanders, Ronald J.A.; DiMauro, Salvatore; Blanck, Thomas J.J.

In: Journal of the American College of Cardiology, Vol. 42, No. 11, 03.12.2003, p. 1994-1999.

Research output: Contribution to journalArticle

Schlame, M, Kelley, RI, Feigenbaum, A, Towbin, J, Heerdt, PM, Schieble, T, Wanders, RJA, DiMauro, S & Blanck, TJJ 2003, 'Phospholipid Abnormalities in Children with Barth Syndrome', Journal of the American College of Cardiology, vol. 42, no. 11, pp. 1994-1999. https://doi.org/10.1016/j.jacc.2003.06.015
Schlame, Michael ; Kelley, Richard I. ; Feigenbaum, Annette ; Towbin, Jeffrey ; Heerdt, Paul M. ; Schieble, Thomas ; Wanders, Ronald J.A. ; DiMauro, Salvatore ; Blanck, Thomas J.J. / Phospholipid Abnormalities in Children with Barth Syndrome. In: Journal of the American College of Cardiology. 2003 ; Vol. 42, No. 11. pp. 1994-1999.
@article{2fe097b37a7549fabb6523f034f681e4,
title = "Phospholipid Abnormalities in Children with Barth Syndrome",
abstract = "OBJECTIVES: We sought to identify characteristic lipid abnormalities in patients with Barth syndrome (BTHS) and to correlate the lipid profile to phenotype and genotype. BACKGROUND: Barth syndrome typically includes cardiomyopathy, skeletal myopathy, neutropenia, growth retardation, and 3-methylglutaconic aciduria, and it is commonly associated with mutations in the tafazzin (TAZ) gene, whose products are homologous to phospholipid acyltransferases. However, clinical features of BTHS have also been found in patients with normal TAZ gene. METHODS: We analyzed molecular species of phospholipids in left and right ventricle, skeletal muscle, platelets, lymphoblasts, and fibroblasts from 19 children with BTHS (positive TAZ mutation), 6 children with BTHS-like syndromes (wild-type TAZ), 4 children with isolated cardiomyopathy (wild-type TAZ), and various controls. RESULTS: Cardiolipin, the specific lipid found only in mitochondria, was decreased in all tissues from BTHS patients, whereas concentrations of other phospholipids were normal. The molecular composition of cardiolipin was altered in all tissues from BTHS patients. The molecular compositions of phosphatidylcholine and phosphatidylethanolamine were altered in the heart. Cardiolipin abnormalities were only found in children with true BTHS, not in children with BTHS-like disease or with isolated cardiomyopathy. The degree of cardiolipin deficiency was tissue-specific but did not correlate with severity or specific phenotypic expression of BTHS. CONCLUSIONS: Abnormal cardiolipin is a specific diagnostic marker of cardiomyopathies caused by TAZ mutations. These mutations lead to alterations in the fatty acid composition of several phospholipids, supporting the idea that TAZ encodes a human acyltransferase.",
author = "Michael Schlame and Kelley, {Richard I.} and Annette Feigenbaum and Jeffrey Towbin and Heerdt, {Paul M.} and Thomas Schieble and Wanders, {Ronald J.A.} and Salvatore DiMauro and Blanck, {Thomas J.J.}",
year = "2003",
month = "12",
day = "3",
doi = "10.1016/j.jacc.2003.06.015",
language = "English (US)",
volume = "42",
pages = "1994--1999",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "11",

}

TY - JOUR

T1 - Phospholipid Abnormalities in Children with Barth Syndrome

AU - Schlame, Michael

AU - Kelley, Richard I.

AU - Feigenbaum, Annette

AU - Towbin, Jeffrey

AU - Heerdt, Paul M.

AU - Schieble, Thomas

AU - Wanders, Ronald J.A.

AU - DiMauro, Salvatore

AU - Blanck, Thomas J.J.

PY - 2003/12/3

Y1 - 2003/12/3

N2 - OBJECTIVES: We sought to identify characteristic lipid abnormalities in patients with Barth syndrome (BTHS) and to correlate the lipid profile to phenotype and genotype. BACKGROUND: Barth syndrome typically includes cardiomyopathy, skeletal myopathy, neutropenia, growth retardation, and 3-methylglutaconic aciduria, and it is commonly associated with mutations in the tafazzin (TAZ) gene, whose products are homologous to phospholipid acyltransferases. However, clinical features of BTHS have also been found in patients with normal TAZ gene. METHODS: We analyzed molecular species of phospholipids in left and right ventricle, skeletal muscle, platelets, lymphoblasts, and fibroblasts from 19 children with BTHS (positive TAZ mutation), 6 children with BTHS-like syndromes (wild-type TAZ), 4 children with isolated cardiomyopathy (wild-type TAZ), and various controls. RESULTS: Cardiolipin, the specific lipid found only in mitochondria, was decreased in all tissues from BTHS patients, whereas concentrations of other phospholipids were normal. The molecular composition of cardiolipin was altered in all tissues from BTHS patients. The molecular compositions of phosphatidylcholine and phosphatidylethanolamine were altered in the heart. Cardiolipin abnormalities were only found in children with true BTHS, not in children with BTHS-like disease or with isolated cardiomyopathy. The degree of cardiolipin deficiency was tissue-specific but did not correlate with severity or specific phenotypic expression of BTHS. CONCLUSIONS: Abnormal cardiolipin is a specific diagnostic marker of cardiomyopathies caused by TAZ mutations. These mutations lead to alterations in the fatty acid composition of several phospholipids, supporting the idea that TAZ encodes a human acyltransferase.

AB - OBJECTIVES: We sought to identify characteristic lipid abnormalities in patients with Barth syndrome (BTHS) and to correlate the lipid profile to phenotype and genotype. BACKGROUND: Barth syndrome typically includes cardiomyopathy, skeletal myopathy, neutropenia, growth retardation, and 3-methylglutaconic aciduria, and it is commonly associated with mutations in the tafazzin (TAZ) gene, whose products are homologous to phospholipid acyltransferases. However, clinical features of BTHS have also been found in patients with normal TAZ gene. METHODS: We analyzed molecular species of phospholipids in left and right ventricle, skeletal muscle, platelets, lymphoblasts, and fibroblasts from 19 children with BTHS (positive TAZ mutation), 6 children with BTHS-like syndromes (wild-type TAZ), 4 children with isolated cardiomyopathy (wild-type TAZ), and various controls. RESULTS: Cardiolipin, the specific lipid found only in mitochondria, was decreased in all tissues from BTHS patients, whereas concentrations of other phospholipids were normal. The molecular composition of cardiolipin was altered in all tissues from BTHS patients. The molecular compositions of phosphatidylcholine and phosphatidylethanolamine were altered in the heart. Cardiolipin abnormalities were only found in children with true BTHS, not in children with BTHS-like disease or with isolated cardiomyopathy. The degree of cardiolipin deficiency was tissue-specific but did not correlate with severity or specific phenotypic expression of BTHS. CONCLUSIONS: Abnormal cardiolipin is a specific diagnostic marker of cardiomyopathies caused by TAZ mutations. These mutations lead to alterations in the fatty acid composition of several phospholipids, supporting the idea that TAZ encodes a human acyltransferase.

UR - http://www.scopus.com/inward/record.url?scp=0344010615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344010615&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2003.06.015

DO - 10.1016/j.jacc.2003.06.015

M3 - Article

VL - 42

SP - 1994

EP - 1999

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 11

ER -